findmyKOL
Clinical trialNCT03187795UnknownPhase 2Interventional

Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury

SponsorKessler FoundationEnrollment62Spinal Cord InjuriesUrinary Bladder, Neurogenic
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this research study is to determine the effectiveness and safety of mirabegron compared to oxybutynin chloride immediate release (oxybutynin IR) for a condition called neurogenic detrusor overactivity in individuals with chronic spinal cord injury (SCI).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Kessler Institute for Rehabilitation

    West Orange, New Jersey, United States

    Steven C. Kirshblum, M.D.Todd A. Linsenmeyer, M.D.Trevor A. Dyson-Hudson, M.D.
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Mirabegron →Oxybutynin Chloride IR
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
3 Apr 2019
Primary completion
30 Sept 2021
Completion
30 Mar 2022
Last update posted
17 Dec 2019
Registered enrollment
62
Registry id
NCT03187795
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.